Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism at the Lewis Katz School of Medicine at Temple University, offered insight to Medscape on study results which used the MyPhenome Hungry Gut Test from Phenomix Sciences and which were presented at the American Diabetes Association Scientific Sessions. An analysis of the data of 137 patients in the study suggested that testing whether people have a trait known as abnormal postprandial satiety (APS), or hungry gut, can predict how well they may respond to semaglutide, although it failed to establish this link for tirzepatide. Dr. Rao was not involved in the study.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH